# NOVO NORDISK INC. Expired Good Return Policy

The Novo Nordisk Inc. Expired Good Return Policy governs the return of Novo Nordisk Inc. product purchased directly from Novo Nordisk Inc., products licensed to be distributed by Novo Nordisk Inc., product purchased from U.S. territory-based entities licensed to distribute product and third-party reverse logistics providers processing returns on behalf of U.S. territory Customer(s).

Novo Nordisk Inc. accepts expired good returns and evaluates final reimbursement for all products returned in accordance with the details captured in this policy. Novo Nordisk Inc. reserves the right to make the final determination on the valuation of the return.

Novo Nordisk Inc. utilizes PharmaLink as our authorized Reverse Logistics Provider.

## Terms of Return Policy:

- > Product must be returned to PharmaLink for reimbursement consideration. Product that is not returned to PharmaLink is not eligible for reimbursement.
- Reimbursement consideration begins on the date of product receipt at PharmaLink; not the date of debit memo creation identified by the customer or customer's reverse logistics provider.
- > Credit will be issued on all eligible returns valued at current WAC less 10%; not the value identified by the customer or customer's reverse logistics provider.
- > Ineligible items may be returned for proper disposal; however, no credit will be issued.
- > Eligible partials will be credited for exact quantities returned.
- > Transportation charges are pre-paid by Customer.
- For items purchased directly from Novo Nordisk Inc., credit will be issued to the direct purchasing entity.
- For items purchased from a wholesaler, credit will be issued to the wholesaler.
  - It is the responsibility of the wholesaler to pass the credit to the customer based on the wholesaler's policy.
- > Sales Representatives or Representatives of Novo Nordisk Inc. are not permitted to pick up merchandise from customers for return goods processing.

### Returnable Items - Eligible for Reimbursement:

- Products in original manufactured containers only.
- Products received at PharmaLink within six months of expiration or up to six months post expiration. Expiration date is the last day of the month (mm/yyyy 05/**31**/2018).
- Partial containers (Penfill® and Prefilled® Syringes only).
- Lot number and expiration date must be visible.
- Proof of purchase supplied and/or verified upon request.

### Returnable Items - NOT Eligible for Reimbursement:

- > Product not in original manufactured container.
- Products received at PharmaLink with more than six months prior to expiration and more than six months beyond the expiration date.
- Partial containers (items not contained in the eligible listing above).
- All Hemophilia products, Norditropin®, GlucaGen® HypoKit®, Activella®, Prandin®, ReliOn®, Vagifem®, Macrilen™, Zegalogue® or any product not specifically listed herein which is sold on a non-returnable basis.
- Products involved in a fire, sacrifice, or bankruptcy sale or which have been subject to improper storage conditions.
- Product which has been defaced (containing prescription labels, stickers, handwriting)
- Product determined to be counterfeit, diverted or obtained through an unauthorized source.
- Product destroyed by entity other than PharmaLink.
- Product destroyed by customer or by customer's reverse logistics provider, product samples or product donated by Novo Nordisk Inc. for patient assistance programs or any other authorized program(s).
- Proof of purchase cannot be supplied and/or verified upon request.

#### Reimbursement:

- > Credit will be issued on all eligible returns valued at current WAC less 10%.
- Novo Nordisk Inc. is not responsible for processing fees and/or transportation charges incurred prior to receipt at PharmaLink.
- > Reimbursement will be issued through a credit transaction to the direct purchasing Customer or to the wholesaler associated with the indirect Customer.
- > Novo Nordisk Inc. reserves the right to modify the reimbursement value where applicable.

#### Product Launches / Discontinuation / Divestitures:

> Novo Nordisk Inc. reserves the right to modify reimbursement eligibility in the event of product launch(s) discontinuation(s) or product divestitures(s). Modifications will be stated in the communication distributed announcing the event.

#### Procedure for returning product:

PharmaLink requires a Return Authorization (RA) for all product returned to their facility. Requests for RA's can be made by accessing the PharmaLink website at <a href="https://www.PharmaLinkinc.com">https://www.PharmaLinkinc.com</a> (you will need to upload a PDF copy of your debit memo).

Upon receipt of your box label(s), returns are to be forwarded to the processing facility:

#### **PharmaLink**

Receiving Department PLI-NNI 8285 Bryan Dairy Road, #160 Largo, FL 33777

Novo Nordisk Inc. is not responsible for shipments lost or damaged in-transit.

### Return documentation requirements:

All returns must include documentation outlining the information captured below. Product returned without the required information will be destroyed with no reimbursement issued.

## Information to be provided includes:

- Returnee Customer name, street address, account #, DEA # and/or HIN #, State License #, and contact phone #/e-mail address.
- ➤ Wholesaler name, street address, account #, DEA # and contact phone #/e-mail address.
- > Product Information: Description, NDC#, Quantity, Lot #, expiration date.
- > Reimbursement value being requested both line item and total debit memo value.
- Debit memo number or unique identifier to be clearly identified for reference on the credit document.

#### **Product Recalls:**

Communication and handling of product recalls will be distributed as appropriate at the time an event is identified and reported.

### Return Exceptions:

Novo Nordisk Inc. reserves the right to review exceptions to this policy. Reimbursement considerations are the sole discretion of Novo Nordisk Inc.

Information contained in this document can be modified at any time to comply with laws, regulations, rules, etc. with or without advanced notice.

Questions pertaining to this document can be directed to Novo Nordisk Inc. Customer Service via email (NovoNordiskCustomerService@NovoNordisk.com).

Version 7.0: Effective October 17, 2022